Orgenesis posts record fiscal 1Q profit, $7.3M in revenue as its contact manufacturing business booms

Orgenesis CEO Vered Caplan says the company’s financial performance is indicative of the 'rapid growth' in the cell and gene therapy market

Orgenesis Inc's subsidiary MaSTherCell Global's production facility
The company’s subsidiary MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization

Orgenesis Inc (NASDAQ: ORGS), a developer of advanced cell therapies, announced Thursday that it posted a record fiscal first-quarter profit and $7.3 million in revenue.

The Germantown, Maryland-based biopharmaceutical company said revenue expanded nearly tripled to $7.3 million, compared to $2.6 million for the three months ended February 28, 2018.

Similarly, gross profit tripled to $3 million, compared to $992,000 for the three months ended February 28, 2018.

READ: Orgenesis leads the charge at an exciting time for cell therapy

The company ended the quarter with $14.4 million in cash and around $21.4 million of shareholders’ equity.

“Our financial performance is indicative of the rapid growth in the cell and gene therapy market,” said Orgenesis CEO Vered Caplan.

She chalked up the revenue boost at Orgenesis to “expanding capacity” of the company’s global contract development and manufacturing organization, or CDMO, business and “growing demand” from the company’s client base.

CDMO business on a tear

On the manufacturing side, the company’s subsidiary MaSTherCell Global is a global CDMO and helps companies shorten lead time and lower costs in getting cell therapies and products to the market.

"In order to meet the growing demand for our CDMO services, we are establishing a new, state-of-the-art production site within the Gosselies Biopark in Belgium, which will expand our CDMO capacity with the goal of serving the needs of commercial-stage customers," said Caplan.  

The company is also establishing a new 30,000 square foot manufacturing facility in Houston, Texas, to expand its presence within North America.

Through its point-of-care platform, Orgenesis said it continues to align with regional partners to establish a network of leading healthcare facilities to develop cell and gene therapies. It recently inked an out licensing agreement with HekaBio KK for Japan. It also signed a pact with TheraCell for the clinical development and commercialization of cell and gene therapies in certain European countries.

On the technology side, the company’s subsidiary Orgenesis Ltd, is a pioneer in transdifferentiation, which simply means cell reprograming. It has utilized its proprietary technology to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin-producing cells.

—(Updates on CDMO business, CEO quotes)—

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Orgenesis

Price: 5.9 USD

Market: NASDAQ
Market Cap: $129.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...



Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read